Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma

The ROSORC trial

G. Procopio, E. Verzoni, S. Bracarda, S. Ricci, C. Sacco, L. Ridolfi, C. Porta, R. Miceli, N. Zilembo, E. Bajetta

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.

Original languageEnglish
Pages (from-to)1256-1261
Number of pages6
JournalBritish Journal of Cancer
Volume104
Issue number8
DOIs
Publication statusPublished - Apr 12 2011

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Disease-Free Survival
Hand-Foot Syndrome
Asthenia
sorafenib
Diarrhea
Hypertension
Therapeutics

Keywords

  • immunotherapy
  • interleukin-2
  • renal cell carcinoma
  • sorafenib
  • targeted therapies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma : The ROSORC trial. / Procopio, G.; Verzoni, E.; Bracarda, S.; Ricci, S.; Sacco, C.; Ridolfi, L.; Porta, C.; Miceli, R.; Zilembo, N.; Bajetta, E.

In: British Journal of Cancer, Vol. 104, No. 8, 12.04.2011, p. 1256-1261.

Research output: Contribution to journalArticle

@article{4412973ad1274807ab5a7e1f553b99f6,
title = "Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: The ROSORC trial",
abstract = "Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25{\%} of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.",
keywords = "immunotherapy, interleukin-2, renal cell carcinoma, sorafenib, targeted therapies",
author = "G. Procopio and E. Verzoni and S. Bracarda and S. Ricci and C. Sacco and L. Ridolfi and C. Porta and R. Miceli and N. Zilembo and E. Bajetta",
year = "2011",
month = "4",
day = "12",
doi = "10.1038/bjc.2011.103",
language = "English",
volume = "104",
pages = "1256--1261",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma

T2 - The ROSORC trial

AU - Procopio, G.

AU - Verzoni, E.

AU - Bracarda, S.

AU - Ricci, S.

AU - Sacco, C.

AU - Ridolfi, L.

AU - Porta, C.

AU - Miceli, R.

AU - Zilembo, N.

AU - Bajetta, E.

PY - 2011/4/12

Y1 - 2011/4/12

N2 - Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.

AB - Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC). Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice daily, plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability. Results: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30 weeks with sorafenib alone (P=0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks for those receiving the lower dose. The most common adverse events were asthenia, hand-foot syndrome, hypertension, and diarrhoea. Grade 3-4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment, respectively. Conclusion: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS appeared greater in patients receiving higher-dose IL-2.

KW - immunotherapy

KW - interleukin-2

KW - renal cell carcinoma

KW - sorafenib

KW - targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=79954438593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954438593&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.103

DO - 10.1038/bjc.2011.103

M3 - Article

VL - 104

SP - 1256

EP - 1261

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -